Alligator Bioscience AB Reports Financial Results for Q2 2025 and Provides a Business Update

About this update from Alligator Bioscience Ab

LUND, SE / ACCESS Newswire / July 10, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) BUSINESS UPDATE Mitazalimab Company FINANCIAL SUMMARY FOR Q2 2025 The financial summaries for the quarterly periods ending 30 June 2025 and 30 June 2024 are presented below. FINANCIAL SUMMARY FOR H1 2025 The financial summaries for the half-year periods ending 30 June 2025 and 30 June 2024 are presented below. The full report is attached as a PDF, and is also available on the company's website: https://alligatorbioscience.se/en/investors/financial-reports/ Alligator will host a webinar on Thursday, July 10 2025, at 3 p.m. CEST/ 9 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the April - June 2025 interim report, which will be followed by a Q&A session. The call will be held in English. Attendees need to register by following this link . For further information, please contact: Søren Bregenholt, CEO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 Johan Giléus, CFO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 This information is information that Alligator Bioscience is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-10 08:00 CEST. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments 2025 Q2 EN V1 0 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

View stock analysis, news, and events for Alligator Bioscience Ab